What is pancreatic intraductal oncocytic papillary neoplasm (IPMN)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 17, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Pancreatic Intraductal Oncocytic Papillary Neoplasm (IOPN)

Pancreatic intraductal oncocytic papillary neoplasm (IOPN) is a rare subtype of intraductal papillary mucinous neoplasm (IPMN) characterized by complex arborizing papillae lined by 2-5 layers of cuboidal cells with oncocytic cytoplasm, prominent eccentric nucleoli, and intraepithelial lumina. 1

Definition and Classification

Intraductal oncocytic papillary neoplasms were previously called "intraductal oncocytic papillary neoplasms" but are now classified as one of the four histologic subtypes of IPMN according to the Verona consensus meeting recommendations. The four subtypes of IPMN include:

  1. Gastric type
  2. Intestinal type
  3. Pancreatobiliary type
  4. Oncocytic type

Distinctive Characteristics of IOPN

IOPNs have several features that distinguish them from other IPMN subtypes:

  • Presentation: They typically present as complex, large multilocular cystic lesions rather than the typical IPMN presentation of ductal dilatation or mucin extrusion from the ampulla 1
  • Morphology: Characterized by arborizing papillae lined by 2-5 layers of cuboidal cells with oncocytic cytoplasm and prominent eccentric nucleoli 1
  • Size: Usually large with an average size of 5.5 cm 2
  • Location: Most commonly found in the pancreatic head 2
  • Molecular profile: Unlike other IPMN subtypes, KRAS and GNAS mutations (common in other IPMNs) are seldom detected in IOPNs 1

Clinical Presentation

Patients with IOPN typically present:

  • At an average age of 61 years
  • With equal male/female distribution (ratio 1:1)
  • Either incidentally or with nonspecific abdominal symptoms 2

Radiological Features

On imaging, IOPNs usually appear as:

  • Cystic and solid lesions
  • With or without mural nodules
  • Often requiring multimodal examinations for definitive preoperative diagnosis 2

Malignant Potential

Despite their large size and striking complexity, IOPNs have some unique characteristics regarding malignant potential:

  • Invasive carcinoma is surprisingly rare in these tumors
  • When invasion is present, it is usually very limited in quantity
  • The prognosis is relatively indolent compared to other IPMN subtypes 1
  • All tumors are typically diagnosed as carcinoma in situ or minimally invasive carcinoma 2

Management

The management of IOPN differs from other pancreatic cystic lesions:

  • Surgical resection is necessary due to their malignant potential 2
  • Recurrence after surgical resection is rare but can occur 3
  • Lifelong surveillance of the remnant pancreas following partial pancreatectomy is recommended due to the risk of developing multifocal disease 3

Prognosis

The prognosis of IOPN is generally better than that of other IPMN subtypes:

  • Better outcomes even when metastasis occurs
  • Rare recurrence after surgical resection 2

Differential Diagnosis

IOPN should be differentiated from:

  • Other IPMN subtypes (gastric, intestinal, pancreatobiliary)
  • Mucinous cystic neoplasms
  • Other pancreatic benign cystic lesions
  • Malignant cystic tumors 2, 3

Pathological Diagnosis

Definitive diagnosis is often acquired from:

  • Fine needle aspiration biopsy
  • Postoperative pathology examination 2

The unique histological features of IOPN, including oncocytic cells and complex papillary architecture, are key to distinguishing it from other pancreatic intraductal lesions.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Intraductal oncocytic papillary neoplasm of the pancreas: A systematic review.

Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2019

Related Questions

What is the best course of action for a patient in their 50s with a history of acute pancreatitis secondary to a large intraductal papillary mucinous neoplasm (IPMN), presenting with worsening epigastric pain, fevers, nausea, cholestatic injury, elevated lipase, and hyponatremia?
What is the next best step in treating a patient with a history of intraductal papillary mucinous neoplasm (IPMN) and recurrent pancreatitis, who presents with a ruptured pancreatic tail cyst, pancreatitis, peripancreatic inflammation, adjacent gastritis, and elevated alkaline phosphatase levels?
What is the management approach for a patient with acute pancreatitis and a known pancreatic cystic neoplasm?
What is the appropriate management for a patient with a history of Intraductal Papillary Mucinous Neoplasm (IPMN) and recurrent pancreatitis, who has recently experienced a ruptured pancreatic tail cyst and now presents with thrombocytosis?
What type of surgery is done for patients with pancreatic mucinous neoplasms, including intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs)?
What is the optimal timing for intervention in a pregnant patient with diabetes (Diabetes Mellitus) in Diabetic Ketoacidosis (DKA) at risk for breech presentation and Disseminated Intravascular Coagulation (DIC)?
When is surgical intervention recommended for rupture of the intramuscular segment of the rectus femoris?
What is the acid pocket in the context of gastroesophageal reflux disease (GERD)?
What is the recommended approach for neonatal cardiac screening?
What is tranexamic acid and what is it used for?
What are the recommended tools for psychological assessment in the Intensive Care Unit (ICU)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.